Hungary vs Montenegro: Statin use vs. average non-HDL cholesterol levels
Hungary
3.6
in 2018
Montenegro
3.6
in 2018
Hungary rank
30th
Montenegro rank
30th
Statin use vs. average non-HDL cholesterol levels over time
- Hungary
- Montenegro
How they compare
Hungary currently reports 3.6 against 3.6 in Montenegro, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Hungary ahead.
Hungary ranks 30th and Montenegro ranks 30th of 191 countries.
Across the 4 decades both report, Hungary averaged higher in 3 and Montenegro in 1.
Head to head by decade
| Decade | Hungary | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.3 | 3.95 | 0.35 | Hungary |
| 1990s | 4.19 | 4 | 0.19 | Hungary |
| 2000s | 3.93 | 3.9 | 0.03 | Hungary |
| 2010s | 3.69 | 3.72 | 0.0333 | Montenegro |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Hungary or Montenegro?
- Hungary, at 3.6 against 3.6 in Montenegro as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Hungary and Montenegro?
- 0, with Hungary ahead.
- How many years of comparable data are there for Hungary and Montenegro?
- 39 years are reported by both, from 1980 to 2018.
- How do Hungary and Montenegro rank globally for statin use vs. average non-hdl cholesterol levels?
- Hungary ranks 30th and Montenegro ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.